Q:	What is NSCLC?
A:	NSCLC stands for non-small cell lung cancer.
Q:	What causes NSCLC?
A:	Tobacco smoking is by far the leading cause of lung cancer.1 NSCLC has also been linked to radon exposure.1 Although it is uncommon, some people get NSCLC for no apparent reason.1
Q:	What are the types of NSCLC?
A:	There are two main categories of NSCLC: squamous and non-squamous.2 Non-squamous NSCLC can be further classified as adenocarcinoma or large-cell (undifferentiated) carcinoma.2
Q:	What are the symptoms of NSCLC?
A:	Symptoms of lung cancer may include a cough that does not go away, chest pain that worsens with deep breathing or coughing, and hoarseness.3
Q:	What screenings might my doctor do for NSCLC?
A:	Most lung cancers are not found until they start to cause symptoms.3 If you have any signs or symptoms that suggest you might have lung cancer, your doctor will want to take a medical history to check for risk factors and ask if you have any other symptoms.3 Your doctor will also examine you to look for signs of lung cancer and other health problems.3 If symptoms and/or the results of the physical exam suggest that lung cancer might be present, more involved tests will most likely be needed.3
Q:	What are the shortcomings of the current classification methods?
A:	The methods currently used to classify NSCLC have limitations and may be inaccurate.4-6 It can be hard to tell different types of lung cancers apart—even under a microscope.4,7 Until recently, no single test was available to help doctors accurately tell whether their patients had squamous or non-squamous NSCLC.
Q:	Why was miRview® squamous developed?
A:	miRview® squamous was developed to give doctors a way to tell whether their patients have squamous or non-squamous NSCLC.
Q:	How does miRview® squamous work?
A:	miRview® squamous uses microRNA to tell whether you have squamous or non-squamous NSCLC.
Q:	Why do I need miRview® squamous?
A:	miRview® squamous can tell your doctor whether you have squamous or non-squamous NSCLC. Once your doctor knows whether you have squamous or non-squamous NSCLC, he or she can decide which treatment will work best for you. Because you get the right treatment(s) sooner, you may have a better outcome.
Q:	How does my doctor perform the test?
A:	Your doctor will send a small section of your biopsy to Rosetta Genomics for evaluation.
Q:	How long does it take to get the results of the test?
A:	Your doctor will receive miRview® squamous test results about 10 business days after he or she sends in the sample.
Q:	What does Rosetta Genomics do?
A:	Rosetta Genomics is focused on developing tests based on a recently discovered family of genes called microRNAs. The tests developed by Rosetta Genomics are used primarily in cancer patients.
Q:	How long has Rosetta Genomics been in business?
A:	Rosetta Genomics has been in business for more than 10 years, as it was founded in 2000.
Q:	Where is Rosetta Genomics based?
A:	Rosetta Genomics is an international company with a laboratory in Philadelphia, Pennsylvania, and a research and development center based in Rehovot, Israel.

1. Detailed guide: lung cancer―non-small cell: do we know what causes non-small cell lung cancer? American Cancer Society Web site. Updated October 24, 2008. Accessed February 23, 2009.
2. Overview: lung cancer―non-small cell: what is non-small cell lung cancer? American Cancer Society Web site. Updated November 11, 2008. Accessed February 23, 2009.
3. . Detailed guide: lung cancer―non-small cell: how is non-small cell lung cancer diagnosed? American Cancer Society Web site. Updated October 24, 2008. Accessed February 23, 2009.
4. Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.
5. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1105-1107.
6. Perelman M, Rosenwald S, Spector Y, et al. MicroRNA biomarkers for differential diagnosis of lung tumors. Presented at: United States and Canadian Academy of Pathology Annual Meeting; March 7-13, 2009; Boston, MA. Abstract 1630.
7. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008;132(3):397-401.